Pharmacological validation of TDO as a target for Parkinson’s diseasePaula Perez‐Pardo, Aletta D. Kraneveld, Youri Adolfs et al.|FEBS Journal|2021Cited by 29
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020Jeffrey J. Kooijman, Guido J.R. Zaman, Nicole Willemsen‐Seegers et al.|Frontiers in Oncology|2022Cited by 22
Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1Yvonne Grobben, Guido J.R. Zaman, Judith E. den Ouden et al.|Cancers|2023Cited by 22